Резюме
This article explores the latest dynamics and development trends of the current global foreign trade pharmaceutical industry. It analyzes the growth of the global pharmaceutical trade market size, the changes in the patterns of major importing and exporting countries, as well as the impacts of regional trade agreements. Meanwhile, the article conducts an in-depth study of key trends such as the impact of the Covid -19 пандемия на фармацевтичната верига за доставки, ускорената цифрова трансформация и нарастването на иновативните лекарства и биотехнологични продукти в международната търговия . Най -накрая, тази статия гледа напред към бъдещите перспективи за развитие на външната търговска фармацевтична индустрия, включително потенциала на пазарите на излъчване, движещата се сила на технологичните иновации Разработка .
Въведение
Against the backdrop of global economic integration and the intensification of population aging, the foreign trade pharmaceutical industry is experiencing unprecedented changes and development. As an important industry related to human health, the international trade of pharmaceutical products not only involves economic interests but is also closely related to global public health security. In recent years, affected by multiple factors such as the COVID-19 pandemic, geopolitical tensions, and technological progress, the foreign trade pharmaceutical industry has presented new development trends and challenges. This article will systematically analyze the current market structure, main development trends, and future prospects of the foreign trade pharmaceutical industry, providing a reference for relevant practitioners and policymakers.
I . Настоящата ситуация на глобалния фармацевтичен търговски пазар
The current global pharmaceutical trade market shows a continuous growth trend. According to the latest data from the World Trade Organization (WTO), the total trade volume of global drugs and pharmaceutical products reached 1.2 trillion US dollars in 2022, an increase of approximately 8% compared to the previous year. This growth is mainly driven by factors such as population aging, the Нарастващото разпространение на хроничните заболявания и нарастващото медицинско търсене на развиващите се пазари . Заслужава да се отбележи, че делът на биотехнологичните лекарства и специалните лекарства в търговската структура непрекъснато се увеличава, отразявайки тенденцията на глобалната фармацевтична индустрия към трансформацията на иновациите, което се развива, и на.}}}}} в различните условия на отдела, северно, и ASIA, и ASIA, и ASIA, и ASIA, и ASIA, и ASIA, отразяващи се и ASIA, отразявайки тенденцията на глобалната фармацевтична индустрия към трансформацията на иновациите, което се отразява на иновациите, отразяваща се на тенденцията на глобалната фармацевтична индустрия към иновационното развитие, отразяваща се на иновационното развитие {8}. centers of global pharmaceutical trade. The United States remains the largest importer of pharmaceutical products, while European countries such as Germany and Switzerland maintain important positions as exporting countries. In recent years, China and India, as emerging major pharmaceutical manufacturing countries, have become increasingly prominent, especially in the fields of active pharmaceutical ingredients (APIs) and Общи лекарства ., разчитащи на предимствата на пълната индустриална верига, износът на API в Китай представлява повече от 30% от световния пазарен дял; Индия, със своите предимства на разходите и подобряване на качеството, се превърна в „аптеката на света“.
II . Основните тенденции на фармацевтичната индустрия на външната търговия
The COVID-19 pandemic has had a profound impact on the foreign trade pharmaceutical industry, exposing the vulnerability of the global pharmaceutical supply chain. During the pandemic, the export restrictions of key drugs and medical supplies by various countries led to supply chain disruptions, prompting many countries to re-examine the issue of the self-control and controllability of the pharmaceutical industry. In the post-pandemic era, the pharmaceutical supply chain shows a trend of regionalization and diversification. Multinational pharmaceutical companies are reconfiguring their production bases globally and establishing a more resilient supply chain system.
The digital transformation is reshaping every aspect of the foreign trade pharmaceutical industry. Artificial intelligence and big data analysis are widely applied in drug research and development, clinical trials, and supply chain management, significantly improving efficiency and accuracy. Blockchain technology has shown great potential in drug traceability and anti-counterfeiting, helping to establish a more transparent and trustworthy international trade Околна среда . В допълнение, разработването на трансгранични платформи за електронна търговия предостави нови канали за малки и средни фармацевтични предприятия, за да участват в международната търговия, намалявайки прага на достъпа до пазара .
Innovative drugs and biotechnological products have become new growth points in foreign trade pharmaceuticals. With the breakthroughs in cutting-edge technologies such as gene therapy and cell therapy, the share of biopharmaceuticals in global pharmaceutical trade has continued to expand. In 2022, biopharmaceuticals accounted for more than 25% of the global pharmaceutical export value. At the same time, the international trade activity of specialty drugs such as anti-cancer drugs and drugs for rare diseases has significantly increased, reflecting the growing global demand for precision medicine and high-value drugs. Emerging markets will become an important engine for the growth of the foreign trade pharmaceutical industry. With the economic development and improvement of medical security levels in regions such as Southeast Asia, Latin America, and Africa, the demand for pharmaceutical products in these markets will grow rapidly. It is expected that by 2030, the share of emerging markets in global pharmaceutical consumption will increase from the current 30% to around 40%. Multinational pharmaceutical companies are actively adjusting their strategies and deeply cultivating these potential markets through средства като локализирано производство и сътрудничество .
Technological innovation will continue to drive industry transformation. Breakthroughs in cutting-edge technologies such as mRNA technology, gene editing, and artificial intelligence drug discovery will give birth to a new generation of treatment methods and pharmaceutical products, providing new growth points for international trade. At the same time, digital technologies will further optimize the cross-border trade process of pharmaceuticals, improving the efficiency and transparency of the supply chain. The concepts of environmental protection and sustainable development will also have a profound impact on the industry. Green pharmaceutical manufacturing processes and sustainable packaging solutions will become new dimensions of international competition.
The foreign trade pharmaceutical industry is in a period of profound transformation, facing a situation where opportunities and challenges coexist. The scale of global pharmaceutical trade continues to expand, but risk factors such as supply chain security, technical barriers, and trade policies cannot be ignored. In the future, industry participants need to actively adapt to the trend of digital transformation, strengthen the construction of innovation capabilities, and at the same time pay attention to building a more resilient and sustainable global supply chain system. Governments of various countries should strengthen international cooperation, coordinate regulatory standards, and create a more open and stable policy environment for the international trade of pharmaceutical products. Against the backdrop of the growing global health demand, the foreign trade pharmaceutical industry is expected to achieve more inclusive and sustainable Разработка .
